Published 09/27/2024 1:36:06 p.m.

Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD) - Regeneron Pharmaceuticals (NASDAQ:REGN)

Summary by Benzinga

Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark Phase 3 trials showing Dupixent significantly reduced exacerbations, improved lung function and also improved health-related quality of life COPD is the most prevalent chronic respiratory disease in China, and is a priority within the government's Healthy China 2030 public health plan Dupixent is now approved in four indicat…

0 Articles

All

Left

Center

Right

Benzinga

Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD) - Regeneron Pharmaceuticals (NASDAQ:REGN)

09/27/2024 11:00:04 a.m.·New York, United States

Read Full Article

Investor's Business Daily

Regeneron Snags Its $6 Billion-Potential COPD Approval

Regeneron stock rose Friday after the company won FDA approval for Dupixent in chronic obstructive pulmonary disease, or COPD. The post Regeneron And Sanofi Snag Their $6 Billion-Potential COPD Approval For Dupixent appeared first on Investor's Business Daily.

09/27/2024 1:36:06 p.m.

Read Full Article

Green Stock News

Regeneron Pharmaceuticals: Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD

Green Stock News for the New Green Economy.

09/27/2024 1:35:01 p.m.

Read Full Article

MedPage Today

First-Ever Biologic Approved for COPD

The FDA approved dupilumab (Dupixent) as the first biologic treatment for adults with chronic obstructive pulmonary disease (COPD), Sanofi and Regeneron announced on Friday. An injectable interleukin (IL)-4 and IL-13 pathway inhibitor, dupilumab is indicated as an add-on maintenance treatment for inadequately controlled COPD with an eosinophilic phenotype. Primary support for the approval came from […]

09/27/2024 3:04:56 p.m.·New York, United States

Read Full Article

pipelinereview

Dupixent approved in the US as the first-ever biologic medicine for patients with COPD - Pipelinereview

Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an eosinophilic phenotype Following recent approvals in the EU and China, the US approval is based on two landmark phase 3 studies that showed Dupixent achieved significant reduction in exacerbations, and also showed improvements in lung function and health-related quality of life compared to placebo Dupixent is the leading biologic medicin…

09/27/2024 2:34:25 p.m.

Read Full Article

stocktitan.net

Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD

FDA approves Dupixent for COPD: First biologic treatment reduces exacerbations by 30-34%, improves lung function, and enhances quality of life for adults with eosinophilic phenotype. Groundbreaking option for 300,000 U.S. patients.

09/27/2024 1:35:00 p.m.

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Coverage Details

Total News Sources0

Leaning Left0Leaning Right1Center2Last Updated09/27/2024 11:36:01 p.m.Bias Distribution

67% Center

Bias Distribution

67% of the sources are Center

67% Center

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)

Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD) - Regeneron Pharmaceuticals (NASDAQ:REGN)

0 Articles

0 Articles

Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD) - Regeneron Pharmaceuticals (NASDAQ:REGN)

Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD) - Regeneron Pharmaceuticals (NASDAQ:REGN)

Regeneron Snags Its $6 Billion-Potential COPD Approval

Regeneron Snags Its $6 Billion-Potential COPD Approval

Regeneron Pharmaceuticals: Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD

Regeneron Pharmaceuticals: Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD

First-Ever Biologic Approved for COPD

First-Ever Biologic Approved for COPD

Dupixent approved in the US as the first-ever biologic medicine for patients with COPD - Pipelinereview

Dupixent approved in the US as the first-ever biologic medicine for patients with COPD - Pipelinereview

Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD

Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics